Profit margins, US medicine supplies may get hit: Biocon

Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit margins and affect the affordability of generic medicines. With the US being its largest market, Biocon is strategizing to navigate the impact, considering factors like tariff rates and competitor responses. The company is also focusing on expanding its presence in Europe to mitigate risks.